{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:07:22Z","timestamp":1778904442725,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.ygyno.2012.02.016","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T18:46:23Z","timestamp":1329849983000},"page":"376-380","source":"Crossref","is-referenced-by-count":29,"title":["Prognostic determinants in patients with uterine and ovarian clear carcinoma"],"prefix":"10.1016","volume":"125","author":[{"given":"J. Alejandro","family":"Rauh-Hain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Winograd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitfield B.","family":"Growdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O.","family":"Schorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Boruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross S.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil S.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela G.","family":"del Carmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.02.016_bb0005","series-title":"Histologic typing of ovarian tumors","first-page":"1","article-title":"International histological classification of tumors, number 9","author":"Serov","year":"1973"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0010","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0090-8258(89)90637-9","article-title":"Ovarian clear cell adenocarcinoma","volume":"32","author":"Kennedy","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0015","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1991.9.7.1138","article-title":"Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience","volume":"9","author":"Omura","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0020","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1006\/gyno.1993.1117","article-title":"Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages","volume":"49","author":"O'Brien","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/gyno.1998.5071","article-title":"Clinical characteristics of clear cell carcinoma of the ovary","volume":"70","author":"Behbakht","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2012.02.016_bb0030","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1006\/gyno.1996.0065","article-title":"Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease","volume":"60","author":"Goff","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0090-8258(89)90852-4","article-title":"Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma","volume":"32","author":"Jenison","year":"1989","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2012.02.016_bb0040","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ygyno.2006.08.026","article-title":"Thromboembolic complications in patients with clear cell carcinoma of the ovary","volume":"104","author":"Matsuura","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ygyno.2012.02.016_bb0045","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1634\/theoncologist.11-10-1089","article-title":"Treatment issues in clear cell carcinoma of the ovary: a different entity?","volume":"11","author":"Pectasides","year":"2006","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ygyno.2012.02.016_bb0050","first-page":"284","article-title":"A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy","volume":"31","author":"Rauh-Hain","year":"2010","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90279-T","article-title":"Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases","volume":"40","author":"Abeler","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0060","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/(SICI)1097-0142(19961015)78:8<1740::AID-CNCR14>3.0.CO;2-Y","article-title":"Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern","volume":"78","author":"Abeler","year":"1996","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2012.02.016_bb0065","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/01.pas.0000213296.88778.db","article-title":"Precursors of endometrial clear cell carcinoma","volume":"30","author":"Fadare","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ygyno.2012.02.016_bb0070","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ygyno.2009.02.003","article-title":"Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review","volume":"113","author":"Olawaiye","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2012.02.016_bb0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/j.1600-0412.2000.079004311.x","article-title":"Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma","volume":"79","author":"Sakuragi","year":"2000","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0080","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0303-7207(03)00069-8","article-title":"Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes","volume":"202","author":"Fujita","year":"2003","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0085","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","article-title":"Gene expression profiles of serous, endometroid and clear cell subtypes of ovarian and endometrial cancer","volume":"11","author":"Zorn","year":"2005","journal-title":"Clin Res"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix and endometrium","volume":"105","author":"Creasman","year":"2009","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0095","series-title":"Handbook for reporting results of cancer treatment. Publication no. 48","author":"World Health Organization","year":"1979"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/gyno.1998.4997","article-title":"\u201cRecurrence within 6 months of platinum therapy:\u201d an adequate definition of \u201cplatinum-refractory\u201d ovarian cancer?","volume":"69","author":"Markman","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2012.02.016_bb0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1006\/gyno.1999.5505","article-title":"Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma","volume":"74","author":"Cirisano","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0115","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","article-title":"Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy","volume":"88","author":"Sugiyama","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0090-8258(89)90043-7","article-title":"Clear cell carcinoma of the ovary: a study of 59 cases","volume":"35","author":"Crozier","year":"1989","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2012.02.016_bb0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2005.12.038","article-title":"Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience","volume":"102","author":"Pectasides","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2012.02.016_bb0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2007.11.008","article-title":"Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review","volume":"108","author":"Thomas","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0135","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ctrv.2009.07.002","article-title":"Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives","volume":"35","author":"Yoshida","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ygyno.2012.02.016_bb0140","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1525-1438.2007.01156.x","article-title":"Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma","volume":"18","author":"Rauh-Hain","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0145","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1158\/1078-0432.CCR-09-0365","article-title":"mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary","volume":"15","author":"Mabuchi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ygyno.2012.02.016_bb0150","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1470-2045(09)70368-7","article-title":"Targeted therapies for rare gynaecological cancers","volume":"11","author":"Manchana","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2012.02.016_bb0155","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT00979992. Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer. 2009 Sept 17. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00979992?term=GOG&rank=137."},{"key":"10.1016\/j.ygyno.2012.02.016_bb0160","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01196429. Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer. 2010 Sept 4. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01196429?term=Carboplatin+and+Paclitaxel+followed+by+Temsirolimus&rank=1."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812001424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812001424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T20:39:54Z","timestamp":1593722394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812001424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0090825812001424"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.02.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}